China’s first GM rice gets US FDA approval
By Bai Tiantian,
Global Times
| 01. 22. 2018
A genetically modified (GM) rice product developed by a group of Chinese scientists has acquired the US Food and Drug Administration (FDA) approval, the first such Chinese product allowed to enter the US market.
However, neither China nor the US has approved mass cultivation of the rice amid low acceptance from the Chinese public for GM food.
Huahui No.1 rice, developed by the Huazhong Agricultural University, is genetically engineered to resist a wide range of insects, thus reducing the use of pesticides.
Lin Yongjun, a professor at Huazhong Agricultural University and one of the scientists that developed the rice, told the Global Times on Monday that Huahui No.1 could not be grown in China as "the country has not conducted regional trials nor provided guidelines to examine genetically engineered rice."
Lin said his team might consider growing Huahui No. 1 in Southeast Asian countries, "but our reach is limited and we hope the authorities can provide funding and legal support."
Lin's university received an email from the FDA on January 11 approving the rice.
The email, which was made public...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...